Skip to content

clinical efficacy evaluation about recombinant human nerve growth factor on neurotrophic keratitis

clinical efficacy evaluation about recombinant human nerve growth factor on neurotrophic keratitis

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053592
Enrollment
Unknown
Registered
2021-11-24
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurotrophic keratitis (NK)

Interventions

Sponsors

Xi'an First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. An adult patient diagnosed with neurotrophic keratitis in our hospital was confirmed to be moderate or severe neurotrophic keratopathy according to the latest classification of NK. 2. Patients who have been unsuccessfully treated with antibiotics, artificial tears, corneal nutrients, and contact lenses for at least 4 weeks before treatment. 3. The depth of the lesion is less than 2/3, and there is no dissolution perforation.

Exclusion criteria

Exclusion criteria: 1. Undergoing treatment of infectious keratitis, corneal dystrophy, glaucoma, peripheral ulcerative keratitis, endophthalmitis. 2. History of surgery (laser, refraction) in the first 3 months, history of other eye diseases.

Design outcomes

Primary

MeasureTime frame
Corneal nerve fiber density;Corneal perception;

Countries

China

Contacts

Public ContactHao Mi

Xi'an First Hospital

haomi5292@163.com+86 17795631867

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026